Literature DB >> 17040289

Hepatosplenic gammadelta T-cell lymphoma following seven malaria infections.

Rocío Hassan1, Sergio A L Franco, Claudio Gustavo Stefanoff, Sergio O Romano, Hilda R Diamond, Luiz G P Franco, Héctor N Seuánez, Ilana R Zalcberg.   

Abstract

Hepatosplenic gammadelta T-cell lymphoma (HSTL) is a clinicopathological entity associated with an immunocompromised status in approximately 25% of patients. Herein is described a case of HSTL in a 53-year-old Brazilian man with seven previous malaria infections, initially misdiagnosed as a hyperreactive splenomegaly due to chronic malaria. A characteristic lymphoid infiltrate was observed in spleen, liver and bone marrow sinusoids/sinuses. Neoplastic cells had a CD45RO+, CD2+, CD7+, CD3+, CD5-, CD8+, CD56+, perforin+, FasL-negative, T-cell receptor (TCR)alphabeta-negative, TCRgammadelta+ profile. Analyses of gamma and delta TCR rearrangements confirmed diagnosis of gammadelta T-cell lymphoma by detecting VgammaI/Vdelta1-Jdelta1 clonal rearrangements. Sensitive polymerase chain reaction (PCR) for Plasmodium falciparum, Epstein-Barr virus and herpesvirus-8 failed to demonstrate infection. The disease progressed to a fatal outcome following cutaneous infiltration and leukemic proliferation. The authors also comment on the association of lymphoma and infection, focusing on PCR diagnosis of TCRgamma and delta clonal rearrangements and the presumed pathogenic events leading to HSTL in the context of chronic malaria infection. Initial lymphomagenic stages might not be direct consequences of antigenic stimulation of Vdelta1 T-cells, but might depend on interactions between gammadelta T and B cells during cooperative or regulatory responses to Plasmodium sp.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040289     DOI: 10.1111/j.1440-1827.2006.02027.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

1.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

Review 2.  Hepatosplenic T-cell lymphoma: a rare but challenging entity.

Authors:  Barbara Pro; Pamela Allen; Amir Behdad
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

3.  Malaria protection in beta 2-microglobulin-deficient mice lacking major histocompatibility complex class I antigens: essential role of innate immunity, including gammadelta T cells.

Authors:  Tomoyo Taniguchi; Saoko Tachikawa; Yasuhiro Kanda; Toshihiko Kawamura; Chikako Tomiyama-Miyaji; Changchun Li; Hisami Watanabe; Hiroho Sekikawa; Toru Abo
Journal:  Immunology       Date:  2007-10-03       Impact factor: 7.397

4.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.

Authors:  Martin H Voss; Matthew A Lunning; Jocelyn C Maragulia; Esperanza B Papadopoulos; Jenna Goldberg; Andrew D Zelenetz; Steven M Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-27

5.  Progression of a hepatosplenic gamma delta T-cell leukemia/lymphoma on hyperCVAD/MTX and ara-C: literature review and our institutional treatment approach.

Authors:  Abhijit Saste; Javier Arias-Stella; Philip Kuriakose
Journal:  Clin Case Rep       Date:  2015-11-23

Review 6.  A diversified role for γδT cells in vector-borne diseases.

Authors:  Chen Chen; Aibao Chen; Yanan Yang
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.